BOTHELL, Wash., Jan. 28, 2016 /PRNewswire/ -- Verathon® Inc., a leading manufacturer and marketer of imaging and respiratory medical device solutions, announced the launch of its new portable 3D ultrasound instrument: BladderScan Prime.
With all-new features like a touchscreen interface, live B-mode scanning, and onboard self-diagnostics, BladderScan Prime continues the brand's long history of technological advancement, redefining accuracy and making use by clinicians and technicians easier than ever.
"Prime is built to be a workhorse device in any healthcare environment. It is designed to reduce downtime, which in turn raises quality of care," said David Garner, Global Director of Marketing for the company's Imaging & Scanning Solutions business group. "Prime supports evidence-based catheter management, along with consistent, comfortable assessment of patients."
Prime is designed to help reduce catheter associated urinary tract infections (CAUTI), by reducing the use of catheters. "CAUTI is one of the leading causes of infection in hospitals today, and despite years of efforts, those infection rates aren't improving. We're hoping to change that," Garner said.
With one button press, Prime's VMODE® technology acquires multiple scan planes inside the body, producing a 3‑dimensional quantification of the bladder. Based on this quantification, the instrument automatically calculates and displays urinary bladder volume.
Promoting long and uninterrupted service, reliability is built into the BladderScan Prime system. For example, in the event of a drop, the Prime ultrasound probe has an internal mechanical diagnostic to confirm it's still working properly.
To boost accuracy among users of varying skill levels, BladderScan Prime provides simple and advanced aiming modes; immediate feedback for off-center scans and pubic bone interference; and onboard help/tutorial assistance available at any point in the exam.
"The new BladderScan Prime is a world-class instrument," said Neil Hunn, Verathon President. "It is designed to support reliable outcomes for caregivers and patients, as well as economic goals in a rapidly changing healthcare environment. Prime is a low-maintenance solution for high-impact conditions."
For more than 25 years, BladderScan instruments have been built to meet the demands of tough clinical settings. Assembled by hand in the USA, BladderScan devices are backed by a commitment to best-in-class service and warranty solutions, along with dedicated customer service teams.
About Verathon
Verathon is a global medical device company focused on supporting customers by being their trusted partner, delivering high-quality products that endure over time and ensure clinical and economic utility. Two areas where Verathon has significantly impacted patient care, and become the market leader in each, are bladder volume measurement and airway management. The company's BladderScan portable ultrasound and GlideScope video laryngoscopy systems effectively address unmet needs for healthcare providers and meaningfully raise the standard of care for patients. Verathon, a subsidiary of Roper Technologies, is headquartered in Bothell, Washington, and has international subsidiaries in Canada, Europe and Asia. For more information, please visit www.verathon.com.
About Roper Technologies
Roper Technologies is a diversified technology company and is a constituent of the S&P 500, Fortune 1000, and the Russell 1000 indices. Roper provides engineered products and solutions for global niche markets, including software information networks, medical, water, energy, and transportation. Additional information about Roper is available on the company's website at www.ropertech.com.
For More Information Contact:
David Garner
Global Director of Marketing, Imaging & Scanning Solutions
425-629-5573
[email protected]
BladderScan, the BladderScan symbol, GlideScope, the GlideScope symbol, Verathon, and the Verathon Torch symbol are registered trademarks of Verathon Inc. © 2015.
Video - https://www.youtube.com/watch?v=MDp4nYWJmjM
SOURCE Verathon Inc.
Share this article